Immuani develops solutions for oncology treatments and auto-immune disorders by utilizing AI and ML technology to assist in mapping and to provide insights into the reprogramming of the immune system.
Immunai does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for Immunai will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 10/27/2021 | Series C-1 and C-2 | $1.15B | $XXX.XX | $XXX.XX |
| 2/11/2021 | Series B-1 and B-2 | $240.97MM | $XXX.XX | $XXX.XX |
| 5/14/2020 | Series A, Seed-1, and Seed-2 | $38.16MM | $XXX.XX | $XXX.XX |
